The U.S. Supreme Court is set to hear a bid by Amgen to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a “blatant attempt” to squeeze competitors out of the market.

In January, the company let go of some 300 team members in an attempt to “better manage against industry headwinds,” according to an Amgen spokesperson.

In a complaint filed on Monday night in Manhattan federal court, a Detroit-based pension fund said Amgen artificially inflated its stock price by concealing the dispute over its international tax strategy between July 2020 and April 2022.

Merck & Co. Inc. said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.

AbbVie’s weak forecast suggests that Humira rivals could nibble away at the blockbuster drug’s market share at a faster pace this year than analysts’ projections.

U.S. patients will finally get access to cheaper versions of AbbVie Inc.’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.

Amgen is implementing organizational changes that include laying off approximately 300 team members to “better manage against industry headwinds,” a company spokesperson confirmed to BioSpace via email Monday.

Biotech behemoth Amgen inked a licensing agreement Thursday with Netherlands-based Synaffix for the development of next-generation antibody-drug conjugates. 

A reanalysis of data from the FOURIER trial found a higher risk of cardiovascular death associated with Amgen’s injectable cholesterol therapeutic Repatha (evolocumab), according to a study published last month.

Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.